Sponsored By

an unrestricted educational grant from EMD Serono, Pfizer, and MSD.

{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Expert Perspectives and Practical Guidance on IO Combination Strategies for Advanced Renal Cell Carcinoma

Description

OlogyImage

To access this FREE activity, please login (or register first in a new tab). After login, click on the blue +Cart button and enter the Coupon Code: RCCFREE

Do you find it difficult to keep up to date with clinical trial outcomes of new therapies for advanced renal cell carcinoma? Many physicians find the dynamic field of treatment strategies for advanced RCC daunting, and share a lack of understanding of novel treatments and of how to select patients appropriately. This 1-hour learning activity, containing a 30-minute webcast and two interactive patient cases, is developed to improve your knowledge of the latest immunotherapy (IO) combination strategies regarding the characterization and treatment of advanced RCC. Two leading experts in the field of RCC, Dr David McDermott and Dr Lauren Harshman, discuss the latest data on relevant IO combination strategies, including novel IO/anti-VEGF combinations, and elucidate challenges that still lie ahead. In addition, they offer practical guidance on how to relate this new clinical trial data to your own clinical practice.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, and other HCPs involved in the diagnosis and treatment of patients with RCC.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Discuss the rationale and clinical evidence for IO combination regimens in the treatment of advanced RCC, including immunotherapy with VEGFR TKIs
  2. Evaluate recent clinical trial data assessing IO combination regimens
  3. Explain the impact of emerging IO/anti-angiogenic combination strategies on the care of patients with advanced RCC
  4. Identify effective strategies for the early detection and management of adverse events related to IO and IO combination regimens
  5. Develop a treatment plan that integrates the use of optimal IO drug combinations in patients with advanced RCC by applying the latest evidence to improve patient outcomes
Price: 100.0

The base price of this Activity is $100.00. A discount was provided because this Activity is sponsored by an unrestricted educational grant from EMD Serono, Pfizer, and MSD..

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professions: Physician
Test Code: WEB82019
Published: August 2019
Expires: 8/31/2020
Passing Score: 4/5 (80%)
Authors: David F. McDermott, MD. Professor of Medicine, Dana-Farber/Harvard Cancer Center, Boston, MA, USA

Lauren C. Harshman, MD. Assistant Professor of Medicine, Dana-Farber/Harvard Cancer Center, Boston, MA, USA
Specialties: Nephrology, Oncology, Urology